QLC1101 + pembrolizumab

QLC1101 + pembrolizumab is an investigational combination therapy for advanced or metastatic non-small cell lung cancer (NSCLC). QLC1101 is presumed to be a novel agent but is not documented in public scientific or clinical literature or major clinical trial registries as of September 2025. Pembrolizumab is a monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor on T cells, functioning as a checkpoint inhibitor to enhance immune responses against tumor cells. Combination strategies using pembrolizumab (Keytruda) with novel agents for NSCLC typically seek to exploit pembrolizumab's immunotherapy effects alongside targeted or novel mechanisms of action. As no data are available on QLC1101, its mechanism, developer, or specific target remain uncertain. Pembrolizumab is developed by Merck and widely used in NSCLC and other cancers for its immune checkpoint inhibition.

Other names

QLC1101 + Keytruda